A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Phase 3 Completed 192 enrolled Celltrion

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous CT-P13 in Patients with Moderately to Severely Active Rheumatoid Arthritis

Timeline

Start: 2025-01-03
Primary completion: 2025-06-25
Completion: 2026-04-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Infliximab	Monoclonal antibody	—	Subcutaneous

Indications

No indication recorded.